Close
To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the听hyperlinked听Local Project Reference (LRP)听ID, which will take you to the UCLH Find a Study database.
Additional early phase clinical trials recruiting Sarcoma cohorts may be found in the听Advanced Solid Tumour Trials Portfolio page.
听
听
FaR-RMSAn overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma | |
|---|---|
| Local Project Reference: | |
| Principal Investigator: | Dr.听Maria Michelagnoli |
| Drug Class/ Treatment: | Trial of various Immunotherapy, Targeted Therapy Agents and Radiotherapy. |
| Patient Population: | Newly Diagnosed and Relapsed Rhabdomyosarcoma (RMS) Age听>12 months and 鈮�25 years |
| Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) | |
SPEARHEAD-1A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR鈩� T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma | |
|---|---|
| Local Project Reference: | |
| Principal Investigator: | Dr.听Sandra Strauss |
| Drug Class/ Treatment: | ADP-A2M4 SPEAR鈩� T Cells听-听Genetically Modified T-Cells targeting MAGEA4 (Melanoma-Associated Antigen 4) |
| Patient Population: | Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma Age 16 - 75 |
| Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) | |
LIGHTBEAM-U01 (MK-9999-01a Sub Study)LIGHTBEAM-U01 Sub study 01A: A Phase 1/2 Sub-study to Evaluate the听 Safety and Efficacy of Zilovertamab Vedotin in Paediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumours 听 | |
|---|---|
| Local Project Reference: | 162764 |
| Pincipal Investigator: | Dr Rachel Windsor |
| Drug Class/ Treatment: | Zilovertamab Vedotin -听Antibody-Drug Conjugate |
| Patient Population: | Paediatric Patients (1 - <18 Years):
Paediatric and Young Adult Patients (Birth - 25 Years):
|
| Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) | |
听
